BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 7621688)

  • 1. Insulin sensitivity is unaltered by the use of the Norplant subdermal implant contraceptive.
    Koopersmith TB; Lobo RA
    Contraception; 1995 Mar; 51(3):197-200. PubMed ID: 7621688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate metabolism before and after Norplant removal.
    Konje JC; Odukoya OA; Otolorin EO; Ewings PD; Ladipo OA
    Contraception; 1992 Jul; 46(1):61-9. PubMed ID: 1424624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.
    Sivin I; Lähteenmäki P; Mishell DR; Alvarez F; Diaz S; Ranta S; Grozinger C; Lacarra M; Brache V; Pavez M; Nash H; Stern J
    Contraception; 1997 Nov; 56(5):317-21. PubMed ID: 9437561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of Norplant on glucose metabolism under hyperglycemic hyperinsulinemic conditions.
    Shamma FN; Rossi G; HajHassan L; Penzias AS; Connoly-Diamond M; Jones E; Diamond MP
    Fertil Steril; 1995 Apr; 63(4):767-72. PubMed ID: 7890060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of the effects of subdermal levonorgestrel implant system and long acting progestogen injection method on lipid metabolism.
    Anwar M; Soejono SK; Maruo T; Abdullah N
    Asia Oceania J Obstet Gynaecol; 1994 Mar; 20(1):53-8. PubMed ID: 8172528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use.
    Au CL; Affandi B; Rogers PA
    Contraception; 1994 Nov; 50(5):477-89. PubMed ID: 7859456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.
    Alvarez F; Brache V; Tejada AS; Cochon L; Faundes A
    Contraception; 1998 Oct; 58(4):211-4. PubMed ID: 9866001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives.
    Kojima T; Lindheim SR; Duffy DM; Vijod MA; Stanczyk FZ; Lobo RA
    Am J Obstet Gynecol; 1993 Dec; 169(6):1540-4. PubMed ID: 8267059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.
    Dunson TR; Blumenthal PD; Alvarez F; Brache V; Cochon L; Dalberth B; Glover L; Remsburg R; Vu K; Katz D
    Fertil Steril; 1998 Feb; 69(2):258-66. PubMed ID: 9496339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Norplant implants on liver, lipid and carbohydrate metabolism.
    Singh K; Viegas OA; Loke DF; Ratnam SS
    Contraception; 1992 Feb; 45(2):141-53. PubMed ID: 1559336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
    Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
    Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effects of NORPLANT capsules and NORPLANT-2 rods on clinical chemistry: metabolic changes.
    Singh K; Viegas OA; Ratnam SS
    Ann Acad Med Singap; 1990 Nov; 19(6):833-6. PubMed ID: 2130749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users.
    Darney PD; Taylor RN; Klaisle C; Bottles K; Zaloudek C
    Contraception; 1996 Feb; 53(2):97-100. PubMed ID: 8838486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Norplant implants on the pituitary-adrenal axis function and reserve capacity.
    Toppozada MK; Ramadan M; el-Sawi M; Mehanna MT; Khamis Y; Marzouk S
    Contraception; 1997 Jan; 55(1):7-10. PubMed ID: 9013054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norplant-2 subdermal contraceptive system: experience in Taiwan.
    Lee TY; Yang YS; Tseng LH; Ko TM; Hsu MC; Chuang SM
    J Formos Med Assoc; 1993 May; 92(5):446-50. PubMed ID: 8104598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism.
    Konje JC; Otolorin EO; Ladipo OA
    Am J Obstet Gynecol; 1992 Jan; 166(1 Pt 1):15-9. PubMed ID: 1733189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate postpartum insertion of the norplant contraceptive device.
    Molland JR; Morehead DB; Baldwin DM; Castracane VD; Lasley B; Bergquist CA
    Fertil Steril; 1996 Jul; 66(1):43-8. PubMed ID: 8752609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.